Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:IRON OTCMKTS:OXBDF NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$60.92-0.1%$61.79$43.70▼$86.53$1.94B-1.547,374 shs30,551 shsIRONDisc Medicine$57.770.0%$51.32$30.82▼$68.73$2.00B0.76342,608 shs672,319 shsOXBDFOxford BioMedica$5.00$4.38$3.15▼$5.68$529.80M1.11588 shsN/AVCELVericel$35.34-2.5%$41.54$35.18▼$63.00$1.78B1.32425,716 shs545,056 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio0.00%-3.64%+0.73%+11.39%+21.04%IRONDisc Medicine0.00%+1.51%+11.94%+37.35%+27.25%OXBDFOxford BioMedica0.00%+4.82%+16.92%+21.51%+12.49%VCELVericel0.00%-11.50%-15.90%-13.53%-29.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLTEBelite Bio2.0961 of 5 stars3.52.00.00.02.10.80.6IRONDisc Medicine3.3571 of 5 stars4.52.00.00.03.02.50.0OXBDFOxford BioMedicaN/AN/AN/AN/AN/AN/AN/AN/AVCELVericel3.7792 of 5 stars3.55.00.00.03.90.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 3.00Buy$96.6758.68% UpsideIRONDisc Medicine 3.09Buy$96.7067.39% UpsideOXBDFOxford BioMedica 0.00N/AN/AN/AVCELVericel 3.00Buy$61.1473.01% UpsideCurrent Analyst Ratings BreakdownLatest OXBDF, BLTE, VCEL, and IRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.007/3/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.007/3/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.005/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/AOXBDFOxford BioMedica$111.34M4.76N/AN/A$1.01 per share4.95VCELVericel$238.54M7.46$0.31 per share113.09$5.92 per share5.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)IRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)OXBDFOxford BioMedica-$195.90MN/A0.00N/AN/AN/AN/AN/AN/AVCELVericel$10.36M$0.031,178.3980.32N/A1.25%1.09%0.73%7/31/2025 (Estimated)Latest OXBDF, BLTE, VCEL, and IRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IRONDisc Medicine-$1.17N/AN/AN/AN/AN/A8/8/2025Q2 2025BLTEBelite Bio-$0.42N/AN/AN/AN/AN/A7/31/2025Q2 2025VCELVericel-$0.04N/AN/AN/A$64.61 millionN/A5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AOXBDFOxford BioMedicaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A24.3124.31IRONDisc Medicine0.0437.6537.65OXBDFOxford BioMedicaN/AN/AN/AVCELVericelN/A5.014.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%IRONDisc Medicine83.70%OXBDFOxford BioMedicaN/AVCELVericelN/AInsider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%IRONDisc Medicine4.24%OXBDFOxford BioMedicaN/AVCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableOXBDFOxford BioMedica891105.96 millionN/ANot OptionableVCELVericel30050.34 million46.72 millionOptionableOXBDF, BLTE, VCEL, and IRON HeadlinesRecent News About These CompaniesBank of New York Mellon Corp Sells 9,409 Shares of Vericel Corporation (NASDAQ:VCEL)3 hours ago | marketbeat.comSegall Bryant & Hamill LLC Cuts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)July 19 at 6:33 AM | marketbeat.comVericel to Report Second-Quarter 2025 Financial Results on July 31, 2025July 17, 2025 | globenewswire.comVericel Corporation (NASDAQ:VCEL) Shares Bought by Kornitzer Capital Management Inc. KSJuly 17, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low - Should You Sell?July 16, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 4.8% - What's Next?July 15, 2025 | marketbeat.comNew York State Common Retirement Fund Increases Position in Vericel Corporation (NASDAQ:VCEL)July 15, 2025 | marketbeat.comTimesSquare Capital Management LLC Increases Stake in Vericel Corporation (NASDAQ:VCEL)July 14, 2025 | marketbeat.comPrincipal Financial Group Inc. Buys 7,222 Shares of Vericel Corporation (NASDAQ:VCEL)July 14, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Sells 11,632 Shares of Vericel Corporation (NASDAQ:VCEL)July 4, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from BrokeragesJuly 2, 2025 | marketbeat.comLisanti Capital Growth LLC Acquires 13,585 Shares of Vericel Corporation (NASDAQ:VCEL)June 29, 2025 | marketbeat.comIf EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An OpportunityJune 20, 2025 | finance.yahoo.comVericel Corporation: Moving From Sell To NeutralJune 12, 2025 | seekingalpha.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 11, 2025 | morningstar.comMVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 10, 2025 | globenewswire.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 16, 2025 | investing.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?May 10, 2025 | aaii.comAVericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 9, 2025 | finanznachrichten.deVericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...May 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOXBDF, BLTE, VCEL, and IRON Company DescriptionsBelite Bio NASDAQ:BLTE$60.92 -0.07 (-0.11%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$61.20 +0.27 (+0.45%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Disc Medicine NASDAQ:IRON$57.77 -0.02 (-0.03%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$57.80 +0.03 (+0.05%) As of 07/18/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Oxford BioMedica OTCMKTS:OXBDF$5.00 0.00 (0.00%) As of 07/18/2025Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Vericel NASDAQ:VCEL$35.34 -0.92 (-2.54%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$36.68 +1.34 (+3.79%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
